Log in
NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

$3.87
-0.36 (-8.51 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.80
Now: $3.87
$4.25
50-Day Range
$2.94
MA: $3.71
$4.23
52-Week Range
$2.72
Now: $3.87
$15.44
Volume743,753 shs
Average Volume709,829 shs
Market Capitalization$201.39 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.15
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Read More
Unity Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A
Employees94

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$201.39 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$3.87
-0.36 (-8.51 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock price been impacted by Coronavirus?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, UBX stock has decreased by 28.2% and is now trading at $3.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Unity Biotechnology
.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Unity Biotechnology
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) released its earnings results on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.13.
View Unity Biotechnology's earnings history
.

What price target have analysts set for UBX?

6 equities research analysts have issued twelve-month price targets for Unity Biotechnology's shares. Their forecasts range from $4.00 to $20.00. On average, they anticipate Unity Biotechnology's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price.
View analysts' price targets for Unity Biotechnology
.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Canopy Growth (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and Opko Health (OPK).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
  • Dr. Anirvan Ghosh, Director & CEO (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Moloney Securities Asset Management LLC (0.09%), DekaBank Deutsche Girozentrale (0.02%) and BNP Paribas Arbitrage SA (0.02%).

Which major investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, DekaBank Deutsche Girozentrale, and BNP Paribas Arbitrage SA.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $3.87.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $201.39 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.